VALN Stock Forecast 2025-2026
Distance to VALN Price Targets
VALN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Valneva (VALN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VALN and similar high-potential opportunities.
Latest VALN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, VALN has a bullish consensus with a median price target of $17.00 (ranging from $6.55 to $21.00). Currently trading at $6.79, the median forecast implies a 150.3% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VALN Analyst Ratings
VALN Price Target Range
Latest VALN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VALN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 28, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $17.00 |
| Feb 5, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $18.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Oct 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $20.00 |
| Sep 25, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $23.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Aug 2, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Jul 22, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Jun 24, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| May 31, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| May 23, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| May 13, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| May 8, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $26.00 |
| Mar 22, 2024 | Guggenheim | Evan Wang | Buy | Maintains | $17.00 |
Valneva SE (VALN) Competitors
The following stocks are similar to Valneva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Valneva SE (VALN) Financial Data
Valneva SE has a market capitalization of $576.07M with a P/E ratio of 72.7x. The company generates $172.55M in trailing twelve-month revenue with a -4.7% profit margin.
Revenue growth is +20.4% quarter-over-quarter, while maintaining an operating margin of -27.1% and return on equity of -4.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Valneva SE (VALN) Business Model
About Valneva SE
Develops and commercializes vaccines for infectious diseases.
Valneva SE generates revenue by developing vaccines that address unmet medical needs, particularly for travel and endemic diseases. Its business model includes creating innovative solutions such as its COVID-19 vaccine, VLA2001, and engaging in collaborations with governments and health organizations to enhance public health and pandemic preparedness.
The company specializes in vector-borne diseases and has ongoing projects targeting Lyme disease and chikungunya. Headquartered in France, Valneva plays a critical role in diversifying vaccine availability to combat infectious diseases globally, emphasizing the importance of innovation and regulatory compliance in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
676
CEO
Mr. Thomas Lingelbach
Country
France
IPO Year
2021
Website
valneva.comValneva SE (VALN) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Valneva SE (NASDAQ:VALN) purchasers. Investors can visit bgandg.com/VALN for more information.
The investigation into Valneva SE may indicate potential legal issues, which could affect stock performance and investor confidence, impacting share value and trading decisions.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
1 day agoPomerantz LLP is investigating claims on behalf of Valneva SE (NASDAQ:VALN) investors. Interested parties should contact Danielle Peyton at [email protected] or 646-581-9980.
Valneva SE is under investigation, which may indicate potential legal issues affecting the company's stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Valneva SE (NASDAQ:VALN) investors. Interested parties can find more information at bgandg.com/VALN.
Investigation into Valneva may indicate potential legal issues or financial risks, impacting stock performance and investor sentiment.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Valneva SE (NASDAQ:VALN). Investors can find more information on the firm's website.
The investigation into Valneva may indicate potential legal issues or financial irregularities, which could impact stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating claims for investors who purchased Valneva SE (NASDAQ:VALN). Interested parties can find more information at bgandg.com/VALN.
The investigation into Valneva may signal potential legal issues or financial irregularities, impacting stock performance and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in Valneva SE (NASDAQ:VALN). Affected investors can find more information at bgandg.com/VALN.
The investigation into Valneva could indicate potential legal issues or financial risks, impacting stock performance and investor sentiment regarding the company.
Frequently Asked Questions About VALN Stock
What is Valneva SE's (VALN) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Valneva SE (VALN) has a median price target of $17.00. The highest price target is $21.00 and the lowest is $6.55.
Is VALN stock a good investment in 2025?
According to current analyst ratings, VALN has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VALN stock?
Wall Street analysts predict VALN stock could reach $17.00 in the next 12 months. This represents a 150.3% increase from the current price of $6.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Valneva SE's business model?
Valneva SE generates revenue by developing vaccines that address unmet medical needs, particularly for travel and endemic diseases. Its business model includes creating innovative solutions such as its COVID-19 vaccine, VLA2001, and engaging in collaborations with governments and health organizations to enhance public health and pandemic preparedness.
What is the highest forecasted price for VALN Valneva SE?
The highest price target for VALN is $21.00 from at , which represents a 209.2% increase from the current price of $6.79.
What is the lowest forecasted price for VALN Valneva SE?
The lowest price target for VALN is $6.55 from at , which represents a -3.5% decrease from the current price of $6.79.
What is the overall VALN consensus from analysts for Valneva SE?
The overall analyst consensus for VALN is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are VALN stock price projections?
Stock price projections, including those for Valneva SE, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
